NDA 208114 · Jazz Pharms INC
Defitelio
Defibrotide Sodium · Intravenous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 30, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Mar 30, 2016
Approved uses
1
Original approval plus efficacy supplements
Registered trials
21
4 Phase 3, 3 recruiting
FAERS reports
3,584
3,018 serious, 1,751 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 1, 2025.
DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). ( 1 )
Mechanism: The mechanism of action of defibrotide sodium has not been fully elucidated. In vitro , defibrotide sodium enhances the enzymatic activity of plasmin to hydrolyze fibrin clots. Studies evaluating the pharmacological effects of defibrotide sodium on endothelial cells (ECs) were conducted primarily in the human microvascular endothelial cell line. In vitro , defibrotide sodium increased tissue plasminogen activator (t-PA) and thrombomodulin expression, and decreased von Willebrand factor (vWF) and plasminogen activator inhibitor‑1 (PAI-1) expression, thereby reducing EC activation and...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 30, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelReviewSummary Review
1 products under this application
- DEFITELIO · DEFIBROTIDE SODIUM 200MG/2.5ML (80MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Defibrotide" as an intervention, any sponsor and status, largest first.
- Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND StudyPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00628498 · 1,206 participants · Start Dec 2007 · Primary completion Jul 2016
Drug: Defibrotide; Defibrotide · For: Hepatic Veno-Occlusive Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 125 sites in all
- Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric PatientsPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT02851407 · 372 participants · Start Sep 1, 2016 · Primary completion Oct 20, 2020
Drug: Defibrotide · For: Veno-occlusive Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 114 sites in all
- Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of DefibrotidePivotal-lookingCompleted
European Society for Blood and Marrow TransplantationResearch network
NCT00272948 · 360 participants (planned) · Start Dec 2005 · Primary completion Jan 2009
Drug: Defibrotide; Defibrotide and 1 more · For: Hepatic Veno-Occlusive Disease
Sites: Graz, Austria; Vienna, Austria; Villejuif, France · 30 sites in all
- Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.Pivotal-lookingCompleted
Fundacion para la Formacion e Investigacion Sanitarias de la Region de MurciaAcademic, hospital or other
NCT04348383 · 156 participants · Start Apr 8, 2020 · Primary completion Feb 28, 2023
Drug: Defibrotide; Placebo · For: COVID19
Sites: Cartagena, Spain; Barcelona, Spain; Murcia, Spain · 6 sites in all
- An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)Pivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT03339297 · 152 participants · Start Feb 21, 2018 · Primary completion May 12, 2020
Drug: Defibrotide; Standard of Care · For: Graft-versus-host Disease; Acute-graft-versus-host Disease
Sites: Los Angeles, California; Palo Alto, California; San Francisco, California · 62 sites in all
- Defibrotide in Treating Patients With Liver Damage Following Peripheral Stem Cell TransplantationPivotal-lookingCompleted
Dana-Farber Cancer InstituteAcademic, hospital or other
NCT00003966 · 151 participants · Start Apr 2000 · Primary completion Feb 2006
Drug: defibrotide · For: Veno-occlusive Disease
Sites: Duarte, California; Baltimore, Maryland; Boston, Massachusetts · 9 sites in all
- Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)Pivotal-lookingCompleted
Fadoi Foundation, ItalyAcademic, hospital or other
NCT01718288 · 150 participants · Start Nov 2006 · Primary completion Mar 2011
Drug: iloprost; Standard Treatment (aspirin.....), · For: Peripheral Arterial Disease
Sites: Mercato San Severino, Italy; Bari, Italy; Catania, Italy · 14 sites in all
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant PatientsPivotal-lookingCompleted
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT00358501 · 134 participants · Start Jul 2006 · Primary completion Sep 2008
Drug: Defibrotide · For: Severe Hepatic Veno-Occlusive Disease
Sites: Duarte, California; Palo Alto, California; Denver, Colorado · 25 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use1,245
- venoocclusive disease565
- death465
- venoocclusive liver disease347
- multiple organ dysfunction syndrome343
- intentional product use issue198
- hypotension160
- haemorrhage157
- acute graft versus host disease140
- gastrointestinal haemorrhage123
- sepsis121
- renal failure104
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 68 |
| 2017 | 126 |
| 2018 | 601 |
| 2019 | 505 |
| 2020 | 503 |
| 2021 | 198 |
| 2022 | 474 |
| 2023 | 617 |
| 2024 | 293 |
| 2025 | 120 |
| 2026 | 79 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- Defibrotide Therapy for SARS-CoV-2 ARDS.
Frame D, Scappaticci GB, Braun TM, et al. · Chest 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
- Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Kernan NA, Grupp S, Smith AR, et al. · Br J Haematol 2018 · Clinical Trial, Phase III, Multicenter Study
- Antiplatelet agents for chronic kidney disease.
Natale P, Palmer SC, Saglimbene VM, et al. · Cochrane Database Syst Rev 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S, Topaloglu O, Aggarwal S · Clin Drug Investig 2022 · Meta-Analysis, Systematic Review
- Treatment for superficial infusion thrombophlebitis of the upper extremity.
Di Nisio M, Peinemann F, Porreca E, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Jazz Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.